420 LEXINGTON AVE,, NEW YORK, NY
Citius Oncology Elects Class II Directors at 2026 Annual Meeting
Annual Report to Security Holders
Expands Board with Appointment of Independent Director Jonathan Peri
Reports Strong Commercial Momentum for its Cancer Treatment
Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
Ships First International Order of LYMPHIR™ to Europe
Q1
Q4
FY 2024
Q2
Amended Annual Report
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Definitive Information Statement
Preliminary Information Statement
Definitive Additional Proxy Soliciting Materials
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload
SEC Staff Correspondence